高级检索
当前位置: 首页 > 详情页

Clinical and antibody characteristics reveal diverse signatures of severe and non-severe SARS-CoV-2 patients.

文献详情

资源类型:
Pubmed体系:

收录情况: ◇ 统计源期刊 ◇ 卓越:梯队期刊 ◇ 中华系列

机构: [1]Institute of Medical Biology, Chinese Academy of Medical Sciencesand Peking Union Medical College, Kunming 650118, Yunnan, China [2]Schoolof Basic Medical Science, Kunming Medical University, Kunming 650500,China [3]Yunnan Key Laboratory of Laboratory Medicine, Yunnan ProvinceClinical Research Center for Laboratory Medicine, Yunnan Innovation Teamof Clinical Laboratory and Diagnosis, First Affiliated Hospital of Kunming MedicalUniversity, Kunming 650032, China [4]Medical Examination Center, The FirstPeople’s Hospital of Yueyang City, Yueyang 414000, Hunan, China [5]Departmentof Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730,China [6]School of Global Health, Chinese Center for Tropical Diseases Research,Shanghai Jiao Tong University School of Medicine, One Health Center, ShanghaiJiao Tong University-The University of Edinburgh, Shanghai 200025, China
出处:
ISSN:

摘要:
COVID-19 pandemic continues, clarifying signatures in clinical characters and antibody responses between severe and non-severe COVID-19 cases would benefit the prognosis and treatment.In this study, 119 serum samples from 37 severe or non-severe COVID-19 patients from the First People's Hospital of Yueyang were collected between January 25 and February 18 2020. The clinical features, antibody responses targeting SARS-CoV-2 spike protein (S) and its different domains, SARS-CoV-2-specific Ig isotypes, IgG subclasses, ACE2 competitive antibodies, binding titers with FcγIIa and FcγIIb receptors, and 14 cytokines were comprehensively investigated. The differences between severe and non-severe groups were analyzed using Mann-Whitney U test or Fisher's exact test.Severe group including 9 patients represented lower lymphocyte count, higher neutrophil count, higher level of LDH, total bile acid (TBA) (P < 1 × 10-4), r-glutaminase (P = 0.011), adenosine deaminase (P < 1 × 10-4), procalcitonin (P = 0.004), C-reactive protein (P < 1 × 10-4) and D-dimer (P = 0.049) compared to non-severe group (28 patients). Significantly, higher-level Igs targeting S, different S domains (RBD, RBM, NTD, and CTD), FcγRIIa and FcγRIIb binding capability were observed in a severe group than that of a non-severe group, of which IgG1 and IgG3 were the main IgG subclasses. RBD-IgG were strongly correlated with S-IgG both in severe and non-severe group. Additionally, CTD-IgG was strongly correlated with S-IgG in a non-severe group. Positive RBD-ACE2 binding inhibition was strongly associated with high titers of antibody (S-IgG1, S-IgG3, NTD-IgG, RBD-IgA, NTD-IgA, and CTD-IgA) especially RBD-IgG and CTD-IgG in the severe group, while in the non-severe group, S-IgG3, RBD-IgG, NTD-IgG, and NTD-IgM were correlated with ACE2 blocking rate. S-IgG1, NTD-IgM and S-IgM were negatively associated with illness day in a severe group, while S-IgG3, RBD-IgA, CTD-IgA in the severe group (r = 0.363, P = 0.011) and S-IgG1, NTD-IgA, CTD-IgA in the non-severe group were positively associated with illness day. Moreover, GRO-α, IL-6, IL-8, IP-10, MCP-1, MCP-3, MIG, and BAFF were also significantly elevated in the severe group.Antibody detection provides important clinical information in the COVID-19 process. The different signatures in Ig isotypes, IgG subclasses, antibody specificity between the COVID-19 severe and non-severe group will contribute to future therapeutic and preventive measures development.© 2022. The Author(s).

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 医学
小类 | 1 区 热带医学 1 区 寄生虫学 2 区 传染病学
最新[2023]版:
大类 | 1 区 医学
小类 | 1 区 热带医学 2 区 传染病学 2 区 寄生虫学
第一作者:
第一作者机构: [1]Institute of Medical Biology, Chinese Academy of Medical Sciencesand Peking Union Medical College, Kunming 650118, Yunnan, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:82490 今日访问量:0 总访问量:681 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持:重庆聚合科技有限公司 地址:云南省昆明市西山区金碧路157号